Cancer Genetics – News and Features

A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given researchers and their colleagues a deeper insight into how prostate cancer spreads or metastasizes.

A study reveals more than 3,000 genetic changes in a cancer protection gene that heightens breast and ovarian cancer risk. This research enhances risk assessment for patients, especially those with a family history of cancer.

Researchers found that sphingolipids, rather than serving solely as energy sources, are critical for cancer cells to evade immune responses. Blocking sphingolipid production with existing FDA-approved drugs can enhance immune detection of tumors.

Researchers at Memorial Sloan Kettering Cancer Center have discovered a rare subtype of small cell lung cancer, termed atypical small cell lung carcinoma, affecting younger, non-smoking individuals.

New research has illustrated why a promising cancer drug doesn't work against some breast cancers – and has offered insights for new drugs.

Chatbots could provide an alternative to traditional genetic counseling in helping patients to decide whether to pursue genetic testing.

A recent study highlights the role of sphingolipids in cancer cells' immune evasion strategies. Researchers found that these lipids, crucial for cell membrane stability, help tumors avoid immune detection.

New research may provide a new biological target for immunotherapies designed to destroy spreading cancer cells that are often markers for worsening disease.

A identified 813 potential cancer driver genes via splicing, expanding targets beyond traditional mutation-centric models. Using the "spotter" algorithm, researchers found significant non-overlap with existing mutation databases.

A study reveals that aberrant activation of the MYC oncoprotein drives significant changes in the prostate cancer microenvironment. Researchers found MYC's role in transforming the tissue from inflammatory to immunosuppressive.